Indian pharma majors Sun Pharma, Dr Reddy's and Glenmark on Saturday announced the launch of their generic versions of semaglutide injection used for diabetes and weight management with the molecule behind products like Ozempic and Wegovy going off patent in India.
Other leading drug makers, including Torrent Pharmaceuticals, Alkem Laboratories, USV Ltd and Zydus, have also launched generic versions of the injection. The prices of the generic versions of semaglutide injection are considerably lower than the prices of the innovator, Novo Nordisk.
Sun Pharmaceutical Industries launched its semaglutide injection under the brand names Noveltreat and Sematrinity in India, in all strengths. Noveltreat is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet and increased physical activity and is available in five dose strengths -- 0.25 mg/0.5 ml, 0.5 mg/0.5 ml, 1 mg/0.5 ml, 1.7 mg/0.75 ml, and 2.4 mg/0.75 ml, Sun Pharma said in a statement.
Sematrinity is indicated for treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise and is available in two dose strengths -- 2 mg/1.5 ml and 4 mg/3 ml, it added. Weekly therapy costs from initiation to the highest dose, ranges from approximately Rs 900 to Rs 2,000 for Noveltreat and Rs 750 to Rs 1,300 for Sematrinity, supporting greater affordability, Sun Pharma said.
Dr Reddy’s Laboratories Ltd said it has also launched its injectable semaglutide generic under the brand name Obeda for management of type 2 diabetes in India. The Obeda injection is available in 2 mg and 4 mg strengths and comes in a pre-filled, disposable pen designed for subcutaneous, once-a-week administration. Each pen of both strengths will deliver a minimum of four weekly doses. The cost to the patient will be Rs 4,200 per month for both strengths, Dr Reddy's Laboratories said.
Another homegrown pharma major, Glenmark Pharmaceuticals Ltd, launched its generic version of semaglutide injection under the GLIPIQ brand for management of Type 2 diabetes mellitus. The expected weekly cost of treatment with GLIPIQ vials range from Rs 325 to Rs 440, the company said.
Zydus Lifesciences Ltd also announced the launch of its generic version of semaglutide injection under the brand names Semaglyntm, Mashematm and Altermet. The average monthly cost of the treatment will be about Rs 2,200, the company said in a statement. Its novel pen device will be available for patients in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights.
Last year in December, Danish pharma major Novo Nordisk launched its blockbuster type-2 diabetes treatment injection Ozempic, globally popular for its weight-loss benefits in India with cost ranging from Rs 2,200 per week to monthly cost pegged at Rs 11,175 depending on dose and stage of usage.
Similarly, in March 2025, Eli Lilly and Company (India) also launched its medication for obesity and type 2 diabetes, Mounjaro, in a single-dose vial presentation.
Also read: Cracks in India’s pharmaceutical industry
Follow us
